Welcome back to InSilicoTrials’ Talks! We’re excited to launch our IST Customer Testimonials’ initiative, a series dedicated to hearing directly from our clients. Today, we feature Yann Godfrin, CEO of Axoltis Pharma, who joined us for an insightful in silico chat. Discover why InSilicoTrials was their choice for advancing CNS disorder treatments and the benefits they’ve experienced from in silico technologies.
- Why did you choose InSilicoTrials for your project/needs?
- Specialized Project in CNS Disorders: We are working on a special project focused on CNS (Central Nervous System) disorders. which involves “agnostic indications,” meaning we can target many indications within CNS disorders and neurology.
- Utilization of In Silico Technology: We have a desire to utilize in silico technology, which involves computer simulations, to help select and optimize our next steps in clinical development. This technology aids in determining the best regimen of treatment to maximize the chances of success.
- Company Visibility and Communication: We have acknowledged the visibility of InSilicoTrials due to its social media presence and communication efforts, which helped us easily identify and choose the company. We have also identified other companies, but IST was the one with the best fit according to what we wished to explore.
To sum up, the decision to choose InSilicoTrials was influenced by our company specialization in CNS and InSilicoTrials technological capabilities, as well as its visibility and communication in the field.
- What benefits have you experienced by incorporating in silico approaches into your projects?
- Risk Reduction: in silico approaches help in reducing the risk of development, which is particularly significant for ventures that are inherently risky, like a biotech company
- Increased Chance of Success: Utilizing in silico modeling to predict outcomes of clinical trials allows for better regimen choices, thereby increasing the chances of success. The practical applicability and acceptance by authorities of in silico proposed dosage signify that it could potentially streamline certain processes in clinical trials.
- Aid in Fundraising: The use of in silico methods makes projects more appealing to venture capitalists by demonstrating a well-thought-out approach, thus aiding in fundraising.
- Strategic Advantages: Companies utilizing in silico approaches are deemed to have a strategic advantage over those relying solely on traditional methods, especially when seeking investments and competing in the market.
In conclusion, the integration of in silico methodologies into our operations offers multifaceted benefits ranging from risk mitigation and heightened success rates to aiding in financial backing and ensuring a strategic edge in the competitive landscape.
- In your opinion, what are the key advantages of using in silico methods over traditional approaches in your field?
- De-risking Developmental Process: In silico approaches allow for the de-risking of the developmental process by providing insights and predictions that can be accounted for in the early stages.
- Enhanced Valuation: By reducing risk and increasing the likelihood of success, in silico methods contribute to enhancing the valuation of the projects/companies.
- Clever Investment Opportunity: The speaker suggests that incorporating in silico approaches presents a more “clever bet” to venture capitalists, as it demonstrates a comprehensive and strategic approach to development.
- Optimized Clinical Approaches: The in silico approach optimizes the selection and mobilization in clinical approaches, improving overall development strategies. The mention of “deep technology and deep mathematical approach” suggests that in silico methods might offer more detailed and comprehensive analysis compared to traditional approaches.
- Time Efficiency: In silico models offer time advantages by predicting possible outcomes and thereby allowing for more strategic planning and execution.
To recap, in silico approaches are pivotal in modernizing drug development by significantly reducing risks, optimizing clinical approaches, and allowing for more strategic planning and execution due to their detailed and comprehensive analysis compared to traditional approaches.